Metalyse 25 mg Contraindications

Metalyse is contraindicated in patients with known hypersensitivity to the active substance tenecteplase, gentamicin (a trace residue from the manufacturing process) or to any of the excipients; situations associated with a risk of bleeding such as: significant bleeding disorder at present or within the past 6 months, known haemorrhagic diathesis; any history of central nervous system damage (i.e. neoplasm, aneurysm, intracranial or spinal surgery); severe uncontrolled arterial hypertension; prolonged or traumatic cardiopulmonary resuscitation (>2 minutes) within the past 2 weeks; severe hepatic dysfunction, including hepatic failure, cirrhosis, portal hypertension (oesophageal varices) and active hepatitis; active peptic ulceration; arterial aneurysm and known arterial/venous malformation; neoplasm with increased bleeding risk; acute pericarditis and/or subacute bacterial endocarditis; acute pancreatitis; acute ischaemic stroke without disabling neurological deficit; history or evidence or suspicion of intracranial haemorrhage including subarachnoid haemorrhage; patients with effective anticoagulation (e.g. INR >1.7) (see Bleeding under Precautions).